Whitehawk Enters New Agreement with Hangzhou DAC for ADC Programs

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: May 21 2026

0mins

WHWK-8.02%

Explore Agentic TradingLet AI Trade for You

Source: Newsfilter

New Agreement Signed: Whitehawk Therapeutics has entered into an agreement with Hangzhou DAC for access to CPT113, planning to develop up to five new antibody-drug conjugate (ADC) programs, indicating the company's potential for expansion in cancer treatment.
Core Technology Application: CPT113 serves as the core linker-payload technology for Whitehawk's ADC platform, enhanced by its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process, which is expected to improve ADC stability and therapeutic index, thereby strengthening market competitiveness.
Clinical Trial Progress: Phase 1 dose-escalation trials for HWK-007 and HWK-016 are currently enrolling, with data expected in the first half of 2027, demonstrating the company's execution capability and progress in clinical development.
External Validation Support: Hangzhou DAC's DXC006 presented clinical data at the ASCO meeting, further validating the efficacy and safety of CPT113, which enhances Whitehawk's confidence in its ADC platform and may drive future market acceptance.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy WHWK?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on WHWK

Wall Street analysts forecast WHWK stock price to rise

3 Analyst Rating

1 Buy

2 Hold

0 Sell

Moderate Buy

Current: 4.490

Low

7.00

Averages

7.00

High

7.00

Current: 4.490

Low

7.00

Averages

7.00

High

7.00

Oppenheimer

Jeff Jones

Outperform

maintain

$6 -> $7

2026-05-08

Reason

Oppenheimer

Jeff Jones

Price Target

$6 -> $7

AI Analysis

2026-05-08

maintain

Outperform

Reason

Oppenheimer analyst Jeff Jones raised the firm's price target on Whitehawk Therapeutics to $7 from $6 and keeps an Outperform rating on the shares after the company provided Q1 financial and business update, with two of three clinical trials planned to begin this year underway. Following a preclinical data reveal at AACR, Oppenheimer sees the Whitehawk candidates HWK-007/-016/-206 as well positioned to address their respective targets in the competitive ADC arena.

Citizens

Reni Benjamin

Outperform

initiated

2026-04-16

Reason

Citizens

Reni Benjamin

Price Target

2026-04-16

initiated

Outperform

Reason

Citizens analyst Reni Benjamin initiated coverage of Whitehawk Therapeutics with an Outperform rating and $8 price target. Whitehawk is advancing three antibody-drug conjugates \"against clinically validated targets\" with initial proof of concept data expected in the first half of 2027, the analyst tells investors in a research note. The firm sees the shares as attractive, with 75% downside in a bear case scenario and 150% upside in a bull case scenario. Whitehawk is positioning itself for the next wave of therapeutics going after novel targets which have largely been clinically validated, contends Citizens.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for WHWK

Unlock Now

About WHWK

Whitehawk Therapeutics, Inc., formerly Aadi Bioscience, Inc., is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Its advanced three-asset antibody drug conjugate (ADC) portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. Its assets include HWK-007, HWK-016 and HWK-206. HWK-007 represents a differentiated opportunity to potentially be among the first next-wave ADCs in clinical development for high PTK7-expressing cancers. HWK-016 is the first ADC that targets the membrane-bound portion of MUC16, a glycoprotein often overexpressed in cancers of female origin. HWK-016 is being evaluated in IND-enabling studies. HWK-206 is designed to address the neuronal target, SEZ6, which is often overexpressed in cancers of neuroendocrine origin.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Whitehawk Develops Next-Gen ADC for Small Cell Lung Cancer

3 days agoPRnewswire

SEZ6 Expression Advantage: SEZ6 expression in small cell lung cancer (SCLC) exceeds that of other approved and emerging ADC targets, indicating its clinical potential as an ADC target and offering new treatment options for patients.
Dual Epitope Binding Technology: HWK-206 utilizes a biparatopic approach, suggesting potential advantages in binding and internalization, with preclinical models indicating its performance may surpass other single epitope ADCs, potentially enhancing therapeutic efficacy.
IND Application Plans: An Investigational New Drug application for HWK-206 is expected to be submitted in mid-2026, with a Phase 1 trial planned to start in Q3 2026, marking a significant advancement in the development of treatments for SCLC and neuroendocrine tumors.
Clinical Data Support: The findings will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, further reinforcing SEZ6's clinical significance as an ADC target and potentially boosting HWK-206's market prospects.

Whitehawk Develops Next-Gen ADC for Small Cell Lung Cancer

3 days agoNewsfilter

SEZ6 Expression Analysis: SEZ6 shows expression levels in small cell lung cancer (SCLC) and other neuroendocrine tumors that are at least three times higher than other ADC targets like HER2 and B7-H3, indicating its potential as a clinically meaningful ADC target.
Clinical Development Plans: Whitehawk plans to submit an IND application for HWK-206 in mid-2026, with a Phase 1 trial expected to start in Q3 2026, aimed at evaluating its efficacy in SCLC and neuroendocrine tumors.
Dual Epitope Binding Strategy: HWK-206 utilizes a biparatopic design, which is anticipated to outperform other single epitope ADCs in preclinical models, potentially enhancing drug binding and internalization, thereby improving therapeutic outcomes.
ASCO Presentation: Whitehawk will present a real-world analysis of SEZ6 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, further validating its application potential in neuroendocrine tumors.

Whitehawk Therapeutics Expands Cancer Treatment Pipeline with New Agreement

May 22 2026stocktwits

Pipeline Expansion Agreement: Whitehawk has secured rights to use CPT113 linker-payload technology from Hangzhou DAC, which will allow the company to develop up to five additional internal programs, thereby enhancing its precision therapy capabilities and competitive position in the oncology market.
Funding for Development: The company announced an $87.5 million private placement equity financing earlier this month, which is expected to extend its financial runway into the second half of 2028, with proceeds earmarked for advancing its antibody-drug conjugate (ADC) pipeline to ensure ongoing research and development.
Clinical Trial Progress: Whitehawk currently has two candidates, HWK-007 and HWK-016, enrolling patients in early-stage clinical trials targeting lung, ovarian, and endometrial cancers, while a third program, HWK-206, is on track for regulatory clearance around mid-year.
Market Sentiment Shift: Retail sentiment around WHWK stock shifted from 'bullish' to 'neutral' in the past 24 hours, although message volume decreased; analysts have set a 12-month price target of $6.5, indicating a potential upside of over 51%.

Whitehawk Therapeutics Signs New Agreement with Hangzhou DAC for ADC Programs

May 21 2026PRnewswire

New Agreement Signed: Whitehawk Therapeutics has entered into an agreement with Hangzhou DAC for access to CPT113, planning to develop up to five new antibody-drug conjugate (ADC) programs, indicating the company's potential expansion in cancer treatment.
Core Technology Validation: Data from Hangzhou DAC's DXC006 presented at the ASCO meeting further validate CPT113 as a core linker-payload technology, suggesting its potential success in clinical applications and possibly enhancing Whitehawk's market competitiveness.
Clinical Trial Progress: Phase 1 dose-escalation trials for HWK-007 and HWK-016 are currently enrolling, with data expected in the first half of 2027, which will provide crucial clinical evidence for the company's future ADC projects.
Strategic Development Outlook: Whitehawk plans to submit Investigational New Drug (IND) applications for multiple new programs over the next 12-24 months, demonstrating the company's ongoing investment in cancer drug development and its keen response to market demands.